Free Trial
NASDAQ:GLTO

Galecto Q2 2025 Earnings Report

Galecto logo
$3.00 -0.18 (-5.66%)
Closing price 09/2/2025 03:55 PM Eastern
Extended Trading
$3.17 +0.17 (+5.63%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Galecto EPS Results

Actual EPS
-$2.60
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Galecto Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Galecto Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
Tuesday, August 5, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Galecto's Q3 2025 earnings is scheduled for Friday, November 7, 2025, with a conference call scheduled on Tuesday, November 4, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Galecto Earnings Headlines

Washington prepares for war
While the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much bigger here at home. Emergency powers are being invoked, trillions are being mobilized, and the scale rivals anything we’ve seen since WWII. According to Porter Stansberry and Jeff Brown, a new economic arms race is already underway — one that could reshape markets, redirect capital, and impact billions of lives. They’ve just released an urgent briefing that explains what’s really happening behind the scenes, and which companies are positioned to benefit most.tc pixel
See More Galecto Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Galecto? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Galecto and other key companies, straight to your email.

About Galecto

Galecto (NASDAQ:GLTO), a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

View Galecto Profile

More Earnings Resources from MarketBeat